Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07534709 · ClinicalTrials.gov registry record · Phase 4
Suzetrigine for Opioid-Free Recovery After Cesarean Delivery
A Phase 4 study, sponsored by University of Texas at Austin.
- Not yet
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT07534709: Clinical Trial Phase 4 study, sponsored by University of Texas at Austin.
NCT07534709 is a Phase 4 study that has not yet begun recruiting, run by University of Texas at Austin. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07534709, a Phase 4 study, has not yet begun recruiting, sponsored by University of Texas at Austin.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine whether suzetrigine increases the proportion of patients who remain completely opioid-free from completion of surgery through 72 hours after cesarean delivery. The main question it aims to answer is: Does adjunctive suzetrigine, when added to a standardized multimodal postoperative analgesic regimen, increase the proportion of patients who remain opioid-free during the first 72 hours after cesarean delivery? Researchers will compare suzetrigine to a placebo (a look-alike substance that contains no drug) to evaluate this outcome. Participants will: * Receive either suzetrigine or placebo after cesarean delivery * Receive standard postoperative pain management, including acetaminophen, nonsteroidal anti-inflammatory drugs, and neuraxial morphine * Have opioid medications available as needed for breakthrough pain * Be followed during hospitalization and after discharge to assess pain, recovery, and medication use
Primary Outcome
Proportion of participants who do not receive any opioid medications from completion of cesarean delivery through 72 hours postoperatively.
Interventions
- DRUG Placebo
- DRUG Suzetrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-05 |
| Phase | Phase 4 |
What is known before NCT07534709 opens enrollment
NCT07534709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07534709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07534709 about?
NCT07534709 is a clinical study titled "Suzetrigine for Opioid-Free Recovery After Cesarean Delivery". The goal of this clinical trial is to determine whether suzetrigine increases the proportion of patients who remain completely opioid-free from completion of surgery through 72 hours after cesarean delivery. The main question it aims to answer is: Does adjunctive suzetrigine, when added to a stand...
What is the current status of trial NCT07534709?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07534709?
The interventions under investigation include: Placebo (DRUG), Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT07534709?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07534709's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia